Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | CASP6 | P55212 | 1/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.51 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.51 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4483879 | 0.84 | CASP6 (0.64) | ATMCASP6L3MBTL1POLBGAA | |
| SCHEMBL4482164 | 0.82 | ATM (0.54) | ATMMCL1L3MBTL1SMN1; SMN2POLB | |
| SCHEMBL4482549 | 0.82 | L3MBTL1 (0.58) | ATMMCL1L3MBTL1POLBPRMT1 | |
| SCHEMBL6906323 | 0.81 | CASP6 (0.60) | CASP6SMN1; SMN2POLBGAA | |
| SCHEMBL4443054 | 0.81 | ATM (0.60) | ATMMCL1L3MBTL1SMN1; SMN2POLB | |
| SCHEMBL6906511 | 0.80 | CASP6 (0.59) | CASP6SMN1; SMN2POLB | |
| SCHEMBL6907200 | 0.80 | CASP6 (0.61) | ATMCASP6L3MBTL1SMN1; SMN2POLB | |
| SCHEMBL6909319 | 0.80 | CASP6 (0.61) | CASP6RAB9APOLB | |
| SCHEMBL14712377 | 0.78 | PRMT1 (0.66) | ATML3MBTL1SMN1; SMN2POLBPRMT1 | |
| SCHEMBL4480386 | 0.77 | CASP6 (0.58) | CASP6SMN1; SMN2POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040234622-A1 | Sulfonamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040234622-A1 | Sulfonamide derivatives | PCNA, TOP2A, DDB1 | ATM 83/4885CASP6 334/4885MCL1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.